Jonathan D. Cheng
Impact in
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Cells and Metastasis
Papers in
- Oncology 38
- Peptidase Inhibition and Analysis 21
- Cancer Immunotherapy and Biomarkers 11
- Cancer Cells and Metastasis 3
- Colorectal Cancer Surgical Treatments 3
-
- Head and Neck Cancer Studies 9
- Co-authors
- Tanguy Y. Seiwert (6 shared papers)Jared K. Lunceford (5 shared papers)Terrill K. McClanahan (4 shared papers)Laura Q.M. Chow (5 shared papers)Raanan Berger (2 shared papers)Jennifer Holmes Yearley (3 shared papers)Erin Elizabeth Murphy (3 shared papers)Louis M. Weiner (14 shared papers)
- Journals
- Journal of Clinical Oncology (9 papers)Clinical Cancer Research (5 papers)International Journal of Radiation Oncology*Biology*Physics (3 papers)Journal of Medicinal Chemistry (3 papers)Annals of Surgical Oncology (3 papers)
- Partner nations
- United StatesBelgiumTaiwan
In The Last Decade
Jonathan D. Cheng
78 papers receiving 11.7k citations
Jonathan D. Cheng's Hit Papers
Peers
Comparison fields: 5 of 128
- Otorhinolaryngology 1.2k
- Oncology 7.1k
- Cancer Research 1.7k
- Immunology 2.3k
- Pulmonary and Respiratory Medicine 2.0k
Countries citing papers authored by Jonathan D. Cheng
This map shows the geographic impact of Jonathan D. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan D. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan D. Cheng more than expected).
Fields of papers citing papers by Jonathan D. Cheng
This network shows the impact of papers produced by Jonathan D. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan D. Cheng. The network helps show where Jonathan D. Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan D. Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade Hit paper breakdown → | 2017 | 2539 |
| 2 | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Hit paper breakdown → | 2016 | 1373 |
| 3 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study Hit paper breakdown → | 2016 | 1181 |
| 4 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study Hit paper breakdown → | 2017 | 536 |
| 5 | PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer Hit paper breakdown → | 2017 | 479 |
| 6 | 2005 | 426 | |
| 7 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Hit paper breakdown → | 2018 | 349 |
| 8 | Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study Hit paper breakdown → | 2017 | 333 |
| 9 | 2007 | 315 | |
| 10 | 2016 | 304 | |
| 11 | 2011 | 263 | |
| 12 | 2014 | 234 | |
| 13 | 2007 | 226 | |
| 14 | 2013 | 215 | |
| 15 | 2008 | 208 | |
| 16 | Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. | 2002 | 202 |
| 17 | 2006 | 168 | |
| 18 | 2019 | 162 | |
| 19 | 2018 | 154 | |
| 20 | 2005 | 148 |
About Jonathan D. Cheng
Jonathan D. Cheng is a scholar working on Oncology, Otorhinolaryngology, Cancer Research, Surgery and Cellular and Molecular Neuroscience, having authored 80 papers that have together received 11.9k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (21 papers), Cancer Immunotherapy and Biomarkers (11 papers), Neuropeptides and Animal Physiology (10 papers), Head and Neck Cancer Studies (9 papers), Esophageal Cancer Research and Treatment (9 papers), Protease and Inhibitor Mechanisms (9 papers), Cancer Cells and Metastasis (3 papers) and Colorectal Cancer Surgical Treatments (3 papers). The work is most often cited by research in Otorhinolaryngology (1.2k citations), Oncology (7.1k citations), Cancer Research (1.7k citations), Immunology (2.3k citations) and Pulmonary and Respiratory Medicine (2.0k citations). Jonathan D. Cheng has collaborated with scholars based in United States, Belgium and Taiwan. Frequent co-authors include Tanguy Y. Seiwert, Jared K. Lunceford, Terrill K. McClanahan, Laura Q.M. Chow, Raanan Berger, Jennifer Holmes Yearley, Erin Elizabeth Murphy, Louis M. Weiner, Sarina Anne Piha-Paul and Mark Ayers. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, International Journal of Radiation Oncology*Biology*Physics, Journal of Medicinal Chemistry and Annals of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.